

219 Type 2 Diabetes Mellitus

REFERENCES

1. Virally M, Blicklé JF, Girard J, et al: Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives. *Diabetes Metab* 33: 231, 2007.
2. Gulliford MC, Latinovic R, Charlton J: Diabetes diagnosis, resource utilization, and health outcomes. *Am J Manag Care* 14: 32, 2008.
3. Giorgino F, Laviola L, Leonardini A: Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies. *Diabetes Res Clin Pract* 68: S22, 2005.
4. Boulton AJ, Vinik AI, Arezzo JC, et al: Diabetic neuropathies: a statement by the American Diabetes Association. *Diabetes Care* 28: 956, 2005.
5. He Z, King GL: Microvascular complications of diabetes. *Endocrinol Metab Clin North Am* 33: 215, 2004.
6. Moghissi ES, Hirsch IB: Hospital management of diabetes. *Endocrinol Metab Clin North Am* 34: 99, 2005.
7. Singh N, Armstrong DG, Lipsky BA: Preventing foot ulcers in patients with diabetes. *JAMA* 293: 217, 2005.
8. Lipsky BA, Berendt AR, Deery HG, et al: Diagnosis and treatment of diabetic foot infections. *Plast Reconstr Surg* 117: 212S, 2006.
9. Butalia S, Palda VA, Sargeant RJ, et al: Does this patient with diabetes have osteomyelitis of the lower extremity? *JAMA* 299: 806, 2008.
10. Mahaffey KW, Granger CB, Toth CA, et al: Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. *J Am Coll Cardiol* 30: 1606, 1997.
11. Ahmed I, Goldstein B: Diabetes mellitus. *Clin Dermatol* 24: 237, 2006.
12. American Diabetes Association: Standards of medical care in diabetes—2008. *Diabetes Care* 31: S12, 2008.
13. Nathan DM, Buse JB, Davidson MB, et al: Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetologia* 49: 1711, 2006.
14. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al: Thiazolidinedione use and bone loss in older diabetic adults. *J Clin Endocrinol Metab* 91: 3349, 2006.
15. DeFronzo RA, Ratner RE, Han J, et al: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. *Diabetes Care* 28: 1092, 2005.
16. Kendall DM, Riddle MC, Rosenstock J, et al: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. *Diabetes Care* 28: 1083, 2005.
17. Uwaifo GI, Ratner RE: Novel pharmacologic agents for type 2 diabetes. *Endocrinol Metab Clin North Am* 34: 155, 2005.
18. American Diabetes Association: Executive summary: standards of medical care in diabetes—2008. *Diabetes Care* 31: S5, 2008.
19. Zammitt NN, Frier BM: Hypoglycemia in type 2 diabetes, pathophysiology, frequency, and effects of different treatment modalities. *Diabetes Care* 28: 2948, 2005.
20. Chelliah A, Burge MR: Hypoglycemia in elderly patients with diabetes mellitus: causes and strategies for prevention. *Drugs Aging* 21: 511, 2004.
21. Fasano C J, O'Malley GF: A prospective trial of octreotide vs. placebo in sulfonylurea-associated hypoglycemia. *Acad Emerg Med* 13: 180, 2006.

■ USEFUL WEB RESOURCES

Advisory Committee on Immunization Practices (ACIP)—<http://www.cdc.gov/vaccines/recs>
National (US) Diabetes Statistics—<http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm>